SCHEMBL12876294

SCHEMBL12876294

CC(=O)c1ccc(CCc2cc(C)cc(-c3csc(Cn4cc(C(=O)O)cn4)n3)c2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.36
KDM4E B2RXH2 5/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
HTT P42858 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ALDH1A1 P00352 3/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
ALKBH1 Q13686 1/20 0.35
KLKB1 P03952 3/20 0.34
EIF4E P06730 1/20 0.34
AKT1 P31749 1/20 0.34
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
NPC1 O15118 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
EGLN1 Q9GZT9 1/20 0.34
PLA2G4A P47712 1/20 0.34
DHODH Q02127 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12875981 0.92 KLKB1 (0.41) RAB9AKDM4EPOLBGAAHTT
SCHEMBL1197745 0.88 ALDH1A1 (0.42) KDM4EHSD17B10ALDH1A1L3MBTL1EIF4E
SCHEMBL12876201 0.86 KLKB1 (0.40) RAB9AALDH1A1L3MBTL1KLKB1EIF4E
SCHEMBL12875968 0.86 L3MBTL1 (0.41) RAB9AKDM4EPOLBGAAHTT
SCHEMBL1198610 0.86 RAB9A (0.46) RAB9AKDM4EPOLBGAAHTT
SCHEMBL12876264 0.84 DHODH (0.34) RAB9AKDM4EPOLBGAAHTT
SCHEMBL12876300 0.84 KLKB1 (0.36) RAB9AKDM4EPOLBGAAHTT
SCHEMBL12875908 0.83 L3MBTL1 (0.39) RAB9AKDM4EPOLBGAAHTT
SCHEMBL12875995 0.81 ALKBH1 (0.48) KDM4EHTTL3MBTL1ALKBH1KLKB1
SCHEMBL12875895 0.81 L3MBTL1 (0.39) RAB9AKDM4EPOLBGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A RAB9A 2507/4885KDM4E 1877/4885POLB 4137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.